IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 594
NA - Nord America 580
AS - Asia 80
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.255
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 579
IE - Irlanda 277
SE - Svezia 186
IT - Italia 81
CN - Cina 71
PL - Polonia 13
BE - Belgio 12
FI - Finlandia 7
FR - Francia 7
DE - Germania 6
IN - India 6
AT - Austria 2
SG - Singapore 2
CA - Canada 1
EU - Europa 1
JP - Giappone 1
NL - Olanda 1
RO - Romania 1
UA - Ucraina 1
Totale 1.255
Salva come PNG Salva come JPEG
Città #
Dublin 275
Chandler 180
Nyköping 99
Ashburn 65
Princeton 37
Medford 33
Des Moines 24
Ann Arbor 13
Messina 13
Brussels 12
Beijing 9
Jinan 9
Dearborn 7
Pozzuolo Martesana 6
Wilmington 6
Hebei 5
Jacksonville 5
Nanjing 5
Haikou 4
Hangzhou 4
Pune 4
Rome 4
Shenyang 4
Tianjin 4
Bremen 3
Fuzhou 3
Mineo 3
Ningbo 3
Trecastagni 3
Zhengzhou 3
Boardman 2
Cambridge 2
Carini 2
Changsha 2
Enna 2
Guangzhou 2
Jiaxing 2
Lanzhou 2
New York 2
Reggio Nell'emilia 2
Seattle 2
Singapore 2
Trezzo Sull'adda 2
Vienna 2
Amsterdam 1
Bitonto 1
Bucharest 1
Fairfield 1
Gurgaon 1
Helsinki 1
Kunming 1
Lappeenranta 1
Nanchang 1
Nürnberg 1
Ottawa 1
Padova 1
Redwood City 1
San Mateo 1
Springfield 1
Taizhou 1
Tappahannock 1
Viersen 1
Vittoria 1
Totale 892
Salva come PNG Salva come JPEG
Nome #
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 75
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 58
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 56
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 54
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 54
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 50
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 44
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 44
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 44
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 42
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 42
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease 41
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 41
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 39
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 35
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 35
A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy 33
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 32
Incident Colorectal Cancer in Inflammatory Bowel Disease 31
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 30
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 30
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 29
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 28
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 27
null 26
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 26
Letter: the clinical course of Crohn's disease—the Sicilian experience 24
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 22
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 21
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 20
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 19
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 19
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 18
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 18
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 17
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 15
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 14
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 12
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 11
null 10
null 10
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 8
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 7
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 7
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 7
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 6
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 6
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 6
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 4
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 4
Standard Therapeutic Approach and New Therapies 2
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 2
Totale 1.355
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.282
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193 0 0 0 0 0 0 0 0 0 0 1 2
2019/202046 5 1 0 0 3 8 4 3 0 8 7 7
2020/2021152 15 12 32 4 15 4 18 5 5 19 16 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023657 39 65 31 61 29 48 15 28 307 12 16 6
2023/2024192 22 30 42 57 17 24 0 0 0 0 0 0
Totale 1.355